Top Markets
#1 Bedrock Bedrock +50.85%
#2 pippin pippin +21.68%
#3 IQ IQ +20.70%
#4 Naoris Protocol Naoris Protocol +17.39%
#5 Irys Irys +16.18%
#6 Magma Finance Magma Finance +15.58%
#7 ETHGas ETHGas +15.36%
#8 Aria.AI Aria.AI +15.19%
#9 パンチ (Punch) パンチ (Punch) +14.59%
#10 Bitway Bitway +12.30%
Coin of the day
Bedrock Bedrock
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classement en actions #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Prix de l'action
$0.16328419
Capitalisation boursière
$204.14K
Changement (1 jour)
4.35%
Changement (1 an)
102.45%
Pays
GB
Échange Fusion Antibodies plc (FAB)

Catégorie

Healthcare
Ratio P/S pour Fusion Antibodies plc (FAB)
Ratio P/S au March 2026 TTM : 9.79
Selon les derniers rapports financiers et le cours de l'action de Fusion Antibodies plc, le ratio cours/ventes actuel (TTM) est 9.79. À la fin de 2024, le ratio P/S était de 1.88.
Historique du ratio P/S pour Fusion Antibodies plc de 2013 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 9.79 226.39%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -63.73%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 1.13%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -44.83%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -37.31%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.90 31.71%
NL